Crossmark

GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin—Diabetes Meets Dermatology: A Brief Narrative Review

Crossref DOI link: https://doi.org/10.1007/s12325-025-03257-w

Published Online: 2025-06-05

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pantazopoulos, Dimitrios

Gouveri, Evanthia

Papi, Massimo

Papazoglou, Dimitrios

Papanas, Nikolaos https://orcid.org/0000-0002-7320-785X
License Information

Text and Data Mining valid from 2025-06-05

Version of Record valid from 2025-06-05
More Information

Article History

Received: 5 May 2025

Accepted: 20 May 2025

First Online: 5 June 2025

Declarations

:

: Dimitrios Pantazopoulos and Massimo Papi has no conflicts of interest. Evanthia Gouveri has attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly and Boehringer Ingelheim; received speaker honoraria by Boehringer Ingelheim and Menarini. Dimitrios Papazoglou declares associations with Menarini, Novo Nordisk, AstraZeneca, Boehringer Ingelheim and Sanofi-Aventis. Nikolaos Papanas has been an advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elpen, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Bayer, Eli Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis.

: This review is based on previously conducted studies and meta-analyses and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below